DOI QR코드

DOI QR Code

Glycididazole Sodium Combined with Radiochemotherapy for Locally Advanced Nasopharyngeal Carcinoma

  • Li, Ming-Yi (The 4th Ward of Radiotherapy Department, Affiliated Cancer Hospital of Gangzhou Medical University) ;
  • Liu, Jin-Quan (The 4th Ward of Radiotherapy Department, Affiliated Cancer Hospital of Gangzhou Medical University) ;
  • Chen, Dong-Ping (The 4th Ward of Radiotherapy Department, Affiliated Cancer Hospital of Gangzhou Medical University) ;
  • Qi, Bin (The 4th Ward of Radiotherapy Department, Affiliated Cancer Hospital of Gangzhou Medical University) ;
  • Liang, Yu-Ying (The 4th Ward of Radiotherapy Department, Affiliated Cancer Hospital of Gangzhou Medical University) ;
  • Yin, Wen-Jing (The 4th Ward of Radiotherapy Department, Affiliated Cancer Hospital of Gangzhou Medical University)
  • Published : 2014.03.30

Abstract

Background: To evaluate efficacy and side effects of glycididazole sodium (CMNa) combined with chemotherapy (cisplatin plus 5-FU/folic acid, PLF) and radiotherapy in treating patients with locally advanced nasopharyngeal carcinoma. Materials and Methods: Patients with III~IV stage nasopharyngeal carcinoma (NPC),were randomly divided into treatment group (46 patients) and control group (45 patients). Both groups received radiotherapy concomitant with PLF chemotherapy. The treatment group at the same time cwas given CMNa ($800mg/m^2$ before radiotherapy), by l h intravenous drip, three times a week. Results: When the dose of radiation was over 60 Gy, complete response rates of nasopharyngeal tumor and lymph node metastases in treatment group were significantly higher than in the control group (93.5% vs 77.8%; 89.1% vs 93.5%, p<0.05). Three months after radiotherapy, complete response rate of nasopharynx cancer and lymph node metastases in treatment group was both 97.8%, again higher than in the control group (84.4% and 82.2%) (p<0.05). In the treatment group, 1, 3, 5 year disease-free survival rates were 95.7%, 86.7% and 54.5%; and in control group, the corresponding disease-free survival rates were 93.3%, 66.2% and 38.6%, respectively, the difference being statistically significant (log-rank =5.887, p=0.015). One, 3, 5 year overall survival rates in two groups of patients were 97.8%, 93.5%, 70.4% and 95.5%, 88.07%, 48.4%, respectively, again with a statistically significant difference (log-rank=6.470, p=0.011). Acute toxicity and long-term radiotherapy related toxicity in the two groups did not differ (p>0.05). Conclusions: Glycididazole sodium could improve curative effects without increasing adverse reactions when treating paitents with locally advanced nasopharyngeal carcinoma.

References

  1. Abbasi AN, Hafiz A, Ali N, et al (2013). Plan dose evaluation of three dimensional conformal radiotherapy planning (3D-CRT) of nasopharyngeal carcinoma (NPC): experience of a tertiary care University Hospital in Pakistan. Asian Pac J Cancer Prev, 14, 5989-93. https://doi.org/10.7314/APJCP.2013.14.10.5989
  2. Cai YL, Li J, Lu AY, et al (2014). Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/ IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 15, 2001-6. https://doi.org/10.7314/APJCP.2014.15.5.2001
  3. Cheah SK, Lau FN, Yusof MM, et al (2013). Treatment outcome with brachytherapy for recurrent nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 14, 6513-8. https://doi.org/10.7314/APJCP.2013.14.11.6513
  4. Chen H, Luo YL, Zhang L, et al (2013). EA-D p45-IgG as a potential biomarker for nasopharyngeal carcinoma diagnosis. Asian Pac J Cancer Prev, 14, 7433-8. https://doi.org/10.7314/APJCP.2013.14.12.7433
  5. Chen L, Hu CS, Chen XZ, et al (2012). Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol, 13, 163-71. https://doi.org/10.1016/S1470-2045(11)70320-5
  6. Deng W, Long L, Li JL, et al (2014). Mortality of major cancers in guangxi, china: sex, age and geographical differences from 1971 and 2005. Asian Pac J Cancer Prev, 15, 1567-74. https://doi.org/10.7314/APJCP.2014.15.4.1567
  7. Guo XG, Xia Y (2013). The Interleukin-18 promoter -607C>A polymorphism contributes to nasopharyngeal carcinoma risk: evidence from a meta-analysis including 1, 886 subjects. Asian Pac J Cancer Prev, 14, 75 https://doi.org/10.7314/APJCP.2013.14.1.75
  8. Jamshed A, Hussain R, Iqbal H (2014). Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 15, 899-904. https://doi.org/10.7314/APJCP.2014.15.2.899
  9. Jiao W, Liu F, Tang FZ, et al (2013). Expression of the Pokemon proto-oncogene in nasopharyngeal carcinoma cell lines and tissues. Asian Pac J Cancer Prev. 14, 6315-9. https://doi.org/10.7314/APJCP.2013.14.11.6315
  10. Kang M, Liu WQ, Qin YT, et al (2013). Long-term efficacy of microwave hyperthermia combined with chemoradiotherapy in treatment of nasopharyngeal carcinoma with cervical lymph node metastases. Asian Pac J Cancer Prev, 14, 7395-400. https://doi.org/10.7314/APJCP.2013.14.12.7395
  11. Karasawa K, Sunamura M, Okamoto A, et al (2008). Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long -term results of a placebo-conrolled randomised study. Radiother Oncol, 87, 326-30. https://doi.org/10.1016/j.radonc.2008.02.007
  12. Li DW, Dong P, Wang F, et al (2013). Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1$\alpha$. Asian Pac J Cancer Prev, 14, 4853-8. https://doi.org/10.7314/APJCP.2013.14.8.4853
  13. Lin JC, Chiang CF, Wang SW, et al (2014). Significance of expression of human METCAM/MUC18 in nasopharyngeal carcinomas and metastatic lesions. Asian Pac J Cancer Prev, 15, 245-52. https://doi.org/10.7314/APJCP.2014.15.1.245
  14. Li Q, Wang JM, Peng Y, et al (2013). Association of DNA base-excision repair XRCC1, OGG1 and APE1 gene polymorphisms with nasopharyngeal carcinoma susceptibility in a Chinese population. Asian Pac J Cancer Prev, 14, 5145-51 https://doi.org/10.7314/APJCP.2013.14.9.5145
  15. Li CH, Wu DF, Ding H, et al (2014). Berberine hydrochloride impact on physiological processes and modulation of twist levels in nasopharyngeal carcinoma CNE-1 Cells. Asian Pac J Cancer Prev, 15, 1851-7. https://doi.org/10.7314/APJCP.2014.15.4.1851
  16. Sun XJ, Liu H, Zhang P, et al (2013). miR-10b promotes migration and invasion in nasopharyngeal carcinoma cells. Asian Pac J Cancer Prev, 14, 5533-7. https://doi.org/10.7314/APJCP.2013.14.9.5533
  17. Xiang L, Wang Y, Xu BQ, et al (2013). Preliminary results of a phase I/II study of simultaneous boost irradiation radiotherapy for locally advanced nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 14, 7569-76. https://doi.org/10.7314/APJCP.2013.14.12.7569
  18. Xie YJ, Long ZF, He XS (2013). Involvement of EBV-encoded BART-miRNAs and dysregulated cellular miRNAs in nasopharyngeal carcinoma genesis. Asian Pac J Cancer Prev, 14, 5637-44. https://doi.org/10.7314/APJCP.2013.14.10.5637

Cited by

  1. Five miRNAs as Novel Diagnostic Biomarker Candidates for Primary Nasopharyngeal Carcinoma vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7575
  2. Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6011